CiteFacts · FDA Drug Shortages · FDA source
Sufentanil Citrate Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Hikma Pharmaceuticals USA, Inc. | Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05) | Unavailable | 08/13/2026 |
| Hospira, Inc., a Pfizer Company | Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21) | Unavailable | 08/07/2026 |
Source facts
Grouped generic ingredient: Sufentanil Citrate Injection · 4 package records · Latest FDA row update: 08/13/2026
Therapeutic categories: Analgesia/Addiction, Pediatric
Dosage forms: Injection
Routes: EPIDURAL, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.